DE3587873D1 - Kontrollierte Oxydation von mikrobiell hergestellten Cysteine enthaltenden Proteinen. - Google Patents
Kontrollierte Oxydation von mikrobiell hergestellten Cysteine enthaltenden Proteinen.Info
- Publication number
- DE3587873D1 DE3587873D1 DE3587873T DE3587873T DE3587873D1 DE 3587873 D1 DE3587873 D1 DE 3587873D1 DE 3587873 T DE3587873 T DE 3587873T DE 3587873 T DE3587873 T DE 3587873T DE 3587873 D1 DE3587873 D1 DE 3587873D1
- Authority
- DE
- Germany
- Prior art keywords
- synthetic
- oxidizing agent
- microbially produced
- proteins containing
- controlled oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59435184A | 1984-03-28 | 1984-03-28 | |
US06/661,902 US4530787A (en) | 1984-03-28 | 1984-10-17 | Controlled oxidation of microbially produced cysteine-containing proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3587873D1 true DE3587873D1 (de) | 1994-08-11 |
DE3587873T2 DE3587873T2 (de) | 1994-10-20 |
Family
ID=27081941
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3587873T Expired - Lifetime DE3587873T2 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxydation von mikrobiell hergestellten Cysteine enthaltenden Proteinen. |
DE3588226T Expired - Lifetime DE3588226D1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxidation von mikrobiell herstellten, Cystein-enthaltenden Proteinen |
DE198585103559T Pending DE156354T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3588226T Expired - Lifetime DE3588226D1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte Oxidation von mikrobiell herstellten, Cystein-enthaltenden Proteinen |
DE198585103559T Pending DE156354T1 (de) | 1984-03-28 | 1985-03-26 | Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen. |
Country Status (5)
Country | Link |
---|---|
US (1) | US4530787A (de) |
EP (2) | EP0156354B1 (de) |
AT (2) | ATE108186T1 (de) |
CA (1) | CA1233172A (de) |
DE (3) | DE3587873T2 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
JPS60115528A (ja) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
US4761375A (en) * | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US5248769A (en) * | 1985-06-26 | 1993-09-28 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
US4933433A (en) * | 1986-01-31 | 1990-06-12 | E. I. Du Pont De Nemours And Company | Recombinant interleukin-2 composition and process for making it |
CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
DE3611817A1 (de) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | Verfahren zur renaturierung von proteinen |
US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4777242A (en) * | 1986-10-10 | 1988-10-11 | Phillips Petroleum Company | Purification of recombinant tumor necrosis factor |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
WO1988008428A1 (en) * | 1987-04-28 | 1988-11-03 | Amgen Inc. | Method for purifying granulocyte/macrophage colony stimulating factor |
DE3855986T2 (de) * | 1987-05-11 | 1998-02-05 | Chiron Corp | Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen |
US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US4801691A (en) * | 1987-05-15 | 1989-01-31 | International Minerals & Chemical Corp. | Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions |
US4985544A (en) * | 1987-08-04 | 1991-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for renaturing fish growth hormone |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US5759815A (en) * | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
CA1340586C (en) * | 1988-09-23 | 1999-06-08 | Cetus Corporation | Process for recovering microbially produced interferon-beta |
JP2682061B2 (ja) * | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
US5204256A (en) * | 1989-09-06 | 1993-04-20 | Behringwerke Aktiengesellschaft | Process for the purification of plasminogen activator inhibitor 2 (pai-2) |
US5023323A (en) * | 1990-09-12 | 1991-06-11 | Monsanto Company | Method of somatotropin naturation |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
ATE159260T1 (de) * | 1990-11-23 | 1997-11-15 | Roussel Uclaf | Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins |
DE4105480A1 (de) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US20030171292A1 (en) * | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
WO1994009138A1 (en) * | 1992-10-20 | 1994-04-28 | Cetus Oncology Corporation | Interleukin-6 receptor antagonists |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
DE60230491D1 (de) | 2001-03-29 | 2009-02-05 | Schering Corp | Als ccr5-antagonisten verwendbare aryloxim-piperazine |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
WO2003055442A2 (en) * | 2001-10-15 | 2003-07-10 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
KR20060034286A (ko) | 2003-07-11 | 2006-04-21 | 쉐링 악티엔게젤샤프트 | 개량된 재조합 인간 인터페론-베타-1b 폴리펩티드 |
DK1682178T3 (da) | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet |
EP1729791A2 (de) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Behandlung schwerer, ambulant erworbener pneumonie mittels verabreichung des gewebefaktorinhibitors (tfpi) |
ES2318916B1 (es) * | 2005-02-07 | 2010-03-22 | Chiron Corporation | Procedimiento para preparar aldesleukina para uso farmaceutico. |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
MX2009001198A (es) | 2006-08-16 | 2009-02-11 | Hoffmann La Roche | Inhibidores no nucleosidicos de la transcriptasa inversa. |
WO2008071587A2 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
ES2542153T3 (es) | 2007-05-30 | 2015-07-31 | F. Hoffmann-La Roche Ag | Inhibidores no nucleósidos de la transcriptasa inversa |
US8273561B2 (en) * | 2007-10-05 | 2012-09-25 | Nuron Biotech, Inc. | High pressure treatment of aggregated interferons |
KR101610607B1 (ko) | 2007-12-21 | 2016-04-07 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
CN102892780B (zh) | 2010-03-17 | 2015-07-29 | 通益制药有限公司 | 获得生物活性的重组人g-csf的方法 |
EP2655409A4 (de) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Superagonisten und antagonisten von interleukin-2 |
KR102220006B1 (ko) | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 il2 의 용도 |
EP2768844B1 (de) * | 2011-10-21 | 2016-04-27 | Tanvex Biologics Corp. | Trennung acetylierter proteine von nichtacetylierten proteinen |
US10183061B2 (en) | 2013-06-25 | 2019-01-22 | Icm (Institut Du Cerveau Et De La Moelle Epiniere) | Boosting Treg cells for treating Alzheimer disease and related disorders |
WO2015042707A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-2 fusion proteins and uses thereof |
EP2918285A1 (de) | 2014-03-11 | 2015-09-16 | Université Pierre et Marie Curie (Paris 6) | Interleukin-2 zur Behandlung einer Lebensmittelallergie |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
US10457716B2 (en) | 2014-08-06 | 2019-10-29 | University Of Notre Dame Du Lac | Protein folding and methods of using same |
EP3204119B1 (de) | 2014-10-09 | 2021-06-09 | Dana-Farber Cancer Institute, Inc. | Mehrfach-variabler il-2-dosierungsplan zur behandlung von immunerkrankungen |
KR20180064536A (ko) * | 2015-10-22 | 2018-06-14 | 일투 파마 | Il-2의 약학 조성물 |
EP3596108A4 (de) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Gezielte immuntoleranz |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
JP7433051B2 (ja) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Il-2スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
JP2023516774A (ja) | 2020-03-06 | 2023-04-20 | サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム | 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン-2 |
WO2024121173A1 (en) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061538A (en) * | 1973-04-04 | 1977-12-06 | Sandoz Ltd. | Enzymatically oxidizing interferon |
ZA803943B (en) * | 1979-07-31 | 1981-06-24 | Hoffmann La Roche | Homogeneous fibroblast interferon and method for manufacture thereof |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4405601A (en) * | 1981-05-21 | 1983-09-20 | Cancer Research Center | Extraction and purification of biologically active lymphokines |
US4478744A (en) * | 1982-01-25 | 1984-10-23 | Sherwood Medical Company | Method of obtaining antibodies |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
EP0091539B2 (de) * | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen |
ATE37564T1 (de) * | 1982-04-20 | 1988-10-15 | Sloan Kettering Inst Cancer | Reinigung von interleukin-2. |
JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
GR79124B (de) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
JPH06102034B2 (ja) * | 1983-03-25 | 1994-12-14 | セルテク リミテツド | タンパク質の生産方法 |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
-
1984
- 1984-10-17 US US06/661,902 patent/US4530787A/en not_active Expired - Lifetime
- 1984-11-28 CA CA000468868A patent/CA1233172A/en not_active Expired
-
1985
- 1985-03-26 AT AT85103559T patent/ATE108186T1/de not_active IP Right Cessation
- 1985-03-26 DE DE3587873T patent/DE3587873T2/de not_active Expired - Lifetime
- 1985-03-26 EP EP85103559A patent/EP0156354B1/de not_active Expired - Lifetime
- 1985-03-26 DE DE3588226T patent/DE3588226D1/de not_active Expired - Lifetime
- 1985-03-26 AT AT93203286T patent/ATE196769T1/de not_active IP Right Cessation
- 1985-03-26 EP EP93203286A patent/EP0606673B1/de not_active Expired - Lifetime
- 1985-03-26 DE DE198585103559T patent/DE156354T1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE196769T1 (de) | 2000-10-15 |
DE3587873T2 (de) | 1994-10-20 |
EP0156354A3 (en) | 1987-10-28 |
EP0156354B1 (de) | 1994-07-06 |
ATE108186T1 (de) | 1994-07-15 |
CA1233172A (en) | 1988-02-23 |
DE3588226D1 (de) | 2000-11-09 |
EP0606673B1 (de) | 2000-10-04 |
US4530787B1 (de) | 1993-07-20 |
EP0606673A2 (de) | 1994-07-20 |
DE156354T1 (de) | 1986-03-20 |
US4530787A (en) | 1985-07-23 |
EP0156354A2 (de) | 1985-10-02 |
EP0606673A3 (de) | 1995-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4530787B1 (de) | ||
ES549135A0 (es) | Un metodo para oxidar una proteina recombinante totalmente reducida | |
DE69031219D1 (de) | Stabile zusammensetzungen von askorbinsäure | |
ES8603271A1 (es) | Un metodo de producir una composicion de interleuquina-2 | |
BE904831A (fr) | Composition d'activateur tissulaire du plasminogene. | |
DE3852140D1 (de) | Produktion von Proteinen in aktiven Formen. | |
DE3681185D1 (de) | Methode zur aufloesung und naturation von somatotropin. | |
ATE147167T1 (de) | Oxidative denaturierung von eiweissanalyten | |
ATE82857T1 (de) | Interleukin-2-zusammensetzungen. | |
EP0312358A3 (de) | Methode zur Herstellung intramolekularer Disulfidbrücken in rekombinanten Proteinen in Gegenwart eines Denaturierungsmittels | |
ZA844990B (en) | Low ph hair conditioning and neutralizer conditioning compositions containing amine oxides | |
CA1263590C (en) | CYANIDE-FREE REAGENT FOR THE DETERMINATION OF HEMOGLOBIN | |
ES557404A0 (es) | Procedimiento de dosificacion de anticuerpos dirigidos contra toxinas bacterianas. | |
AU564269B2 (en) | Compositions containing s-adenosyl-l methionine | |
FI872869A0 (fi) | Foerfarande foer stabilisering av enzymet laktoperoxidas i produkter. | |
SU1212247A1 (ru) | Твердый электролит для химического источника тока | |
ATE31623T1 (de) | Injizierbare zusammensetzungen von bbm-928a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV |